Clinical and Research Use of BrainAge

This lecture explores the practical implementation of "Brain Age" as a clinical biomarker for tracking neurodegeneration. Building on the technical background established in previous modules, the lecture demonstrates how Brain Age (specifically the Brain Predicted Age Difference or "Brain-PAD") quantifies complex, heterogeneous aging patterns—such as cortical thinning and ventricular enlargement—more intuitively than simple volumetric measurements. The lecture also focuses on a longitudinal case study of patients with Multiple Sclerosis (MS), utilizing the "Project Y" dataset (a cohort of patients and controls all born in 1966) to identify how lifestyle factors like diet and physical activity correlate with protective effects on Brain-PAD, while higher Brain-PAD scores strongly correlate with increased disability (EDSS scores) and cognitive impairment. The lecture concludes by candidly addressing the "black box" nature of deep learning models, the lack of a standardized gold-standard model, and the critical need for clinical validation before Brain-PAD can be reliably used in patient-facing diagnostic settings.

Learning objectives

By the end of this lecture, students will be able to:

• Understand why Brain Age is a superior intuitive marker compared to isolated volumetric atrophy, as it captures the entire pattern of structural changes across the brain
• Learn how Brain-PAD acts as a marker for neurodegeneration in Multiple Sclerosis, correlating with physical disability (EDSS) and cognitive decline (e.g., SDMT scores) 
• Identify how retrospective lifestyle factors (diet, exercise, smoking) contribute to variance in brain aging, demonstrating the potential for modifiable disease trajectories 
• Master the ability to select Brain Age models based on specific clinical goals, recognizing that models optimized for high precision might "mask" disease-specific atrophy, while others may be more sensitive to pathological deviation
• Recognize the obstacles to clinical adoption, including scanner-related variability, the "black box" nature of deep learning, and the sensitivity of models to clinical-quality scan artifacts (motion, 2D vs. 3D imaging)